%0 Journal Article
%T Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
%A Anand Viswanathan
%A Claire Leurent
%A Eric E. Smith
%A James A. Goodman
%A Jonathan R. Polimeni
%A Linda Frattura
%A Mahmut Edip Gurol
%A Martin M. Bednar
%A Monica Lindsay
%A Ping He
%A Usharbudh Shivraj Sohur
%A Yao Zhang
%A the Ponezumab Trial Study Group
%J Archive of "Annals of Clinical and Translational Neurology".
%D 2019
%R 10.1002/acn3.761
%X Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of ¦Â©\amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double¨Cblind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a novel monoclonal antibody against A¦Â 1¨C40
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469253/